You can assess nothing from "the street" on such a thinly traded stock. The company is completely controlled by its investors who understand the GHDX value. They don't care what the price is today. A stock with a price less than 3 times revenues and no debt with expanding markets is held up for only one reason. The BOD meets next week. Good Luck
Results Presented at AACR Demonstrate Company's Ability to Monitor Bladder Cancer Using Non-Invasive
blood test .... on market in 2016
following me around - ignore and dont engage. TIA
Journal of Surgical Oncology Publishes Study Showing Oncotype DX Score(TM) Result Changes Treatment
Physicians Ranked Oncotype DX DCIS Score Most Important Factor in Treatment Planning
For the last month trading shows the short position has been covering. This morning they took out the stops.
The Bakers and the shorts could have easily hedged with the volume of the last 6 months so I nor anyone here can be sure of the outcome but they wont lose money. I dont have to tell anyone who has followed XOMAs 20 yr history of many disappointments and that includes last years Phase2 trial. Most biotech investors who saw the initial eyeguards Phase2 results had a Wow!... and the ODDS favor meeting the endpoint. 55-70% say analysts ( gutsy eh?) . Verifying the pipeline will finally take XOMA out of the top 10 most hated bios to a darling and double digits in a flash Good Luck
BERKELEY, Calif., July 22, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behçet's disease uveitis, run by its partner Servier, an independent French pharmaceutical research company driven by the pursuit of innovative drugs, did not meet the primary endpoint of time to first acute ocular exacerbation.
"Although the study did not achieve its main objective, we did see signals of drug activity such as preserved visual acuity, less severe ocular exacerbations and a reduced incidence of reported macular edema in patients treated with gevokizumab," said Paul Rubin MD, Senior Vice President Research and Development and Chief Medical Officer. "We will continue to work closely with our partner, Servier, and uveitis experts to conduct a thorough analysis of the data to fully understand gevokizumab's impact on several clinically relevant endpoints."
"The initial observations seen in the secondary endpoints are clinically important and meaningful to both clinicians and Behçet's disease uveitis patients," stated Dr. Ilknur Tugal-Tutkun, international coordinator for the EYEGUARD-B study and Professor of Ophthalmology, Head, Ocular Immunology and Uveitis Service at Istanbul University, Istanbul Faculty of Medicine, Department of Ophthalmology. "We look forward to learning more."
Bakers did not get crushed they sold 25% many months ago and shorted in the meantime. They were the strongest signal that it was in trouble ..FORGET this board as clowns will taunt Lawyers will be here and XOMA will go back to 2 dollar land.